Tech Company Financing Transactions

NGM Biopharmaceuticals Funding Round

NGM Biopharmaceuticals secured a $50 million Series C funding round on 7/19/2013. Backers included Prospect Venture Partners, Rho Ventures and The Column Group.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

333 Oyster Point Blvd.
San Francisco, CA 94080
USA

Phone

(650) 243-5555

Website

www.ngmbio.com

Email Address

[email protected]

Overview

NGM Biopharmaceuticals (Nasdaq: NGM) is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

William Rieflin

        

Chief Executive Officer

David Woodhouse

        

Chief Medical Officer

Alex DePaoli

        

Chief Scientific Officer

Jin-Long Chen

        

Vice President

Wenyan Shen

        

VP - R & D

Hui Tian

        

Browse more venture capital transactions:

Prev: 7/19/2013: Nifti venture capital transaction
Next: 7/19/2013: Zurex Pharma venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary